Agios Pharmaceuticals (NASDAQ: AGIO) said it will not advance tebapivat in sickle cell disease after a Phase 2 trial failed ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE